Supernus Pharmaceuticals Stock Fair Value Calculation – Alaska Department of Revenue Invests $937000 in Supernus Pharmaceuticals
January 7, 2024
🌥️Trending News
The Alaska Department of Revenue recently announced an investment of $937,000 in Supernus Pharmaceuticals ($NASDAQ:SUPN), Inc., a leading pharmaceutical company committed to developing and commercializing innovative products for central nervous system diseases. Supernus’s portfolio includes two U.S. FDA-approved products, Oxtellar XR and Trokendi XR, for the treatment of epilepsy and migraine headaches, respectively. The company also has a robust pipeline of investigational products that are being studied in clinical trials for epilepsy, attention deficit and hyperactivity disorder (ADHD), depression, and neuropathic pain. In addition to the Alaska Department of Revenue’s investment, Supernus has received investments from top-tier venture capital firms and strategic healthcare investors.
Supernus is currently listed on the Nasdaq Global Market and has a market capitalization of over $2 billion. The Alaska Department of Revenue’s investment in Supernus is a great indication of the company’s potential as a leader in the pharmaceutical industry. With its robust product portfolio and clinical development pipeline, Supernus is positioned to become a major player in the CNS space.
Earnings
In the recent earning report of FY2023 Q3 as of September 30 2021, SUPERNUS PHARMACEUTICALS earned a total revenue of 148.46M USD and a net income of 21.56M USD. This represents a decrease of 16.3% from the previous year’s total revenue. However, despite this decline, SUPERNUS PHARMACEUTICALS’ total revenue has increased from 148.46M USD to 153.88M USD over the last three years. This marks the department’s commitment to growing the pharmaceutical industry in Alaska through strategic investments.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Supernus Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 610.53 | 25.62 | 3.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Supernus Pharmaceuticals. More…
| Operations | Investing | Financing |
| 93.69 | 285.94 | -396.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Supernus Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.29k | 372.97 | 16.7 |
Key Ratios Snapshot
Some of the financial key ratios for Supernus Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.6% | -46.4% | 6.7% |
| FCF Margin | ROE | ROA |
| 15.3% | 2.8% | 2.0% |
Price History
This injection came as the company’s stock opened at $27.6 and closed at $27.4, representing a slight decrease of 1.1% from the prior closing price of 27.7. This investment marks an important milestone for Supernus Pharmaceuticals, which is sure to have a positive impact on its financial standing. Live Quote…
Analysis – Supernus Pharmaceuticals Stock Fair Value Calculation
At GoodWhale, we conducted an in-depth analysis of SUPERNUS PHARMACEUTICALS‘s wellbeing and concluded that the fair value of SUPERNUS PHARMACEUTICALS share is around $32.7. This fair price was calculated using our proprietary Valuation Line. Currently, SUPERNUS PHARMACEUTICALS stock is traded at $27.4, representing a fair price that is undervalued by 16.2%. We believe this presents an excellent opportunity for investors to capitalize on the current market pricing. More…
Peers
The company’s competitors include Innopharmax Inc, Evoke Pharma Inc, and Medicamen Biotech Ltd.
– Innopharmax Inc ($TPEX:4172)
Innopharmax Inc is a pharmaceutical company with a market cap of 968.22M as of 2022 and a Return on Equity of -12.34%. The company’s main focus is on the development and commercialization of innovative drugs and therapies. Innopharmax has a portfolio of products in various stages of development, including a Phase III clinical trial for its lead product, IPX066, a treatment for Alzheimer’s disease.
– Evoke Pharma Inc ($NASDAQ:EVOK)
Evoke Pharma Inc is a pharmaceutical company that specializes in the development of drugs for the treatment of gastrointestinal disorders. The company has a market cap of 5.27M and a return on equity of -103.41%. Evoke Pharma Inc is a publicly traded company on the Nasdaq exchange under the ticker symbol EVOK.
– Medicamen Biotech Ltd ($BSE:531146)
With a market cap of 11.67B as of 2022, Medicamen Biotech Ltd has a ROE of 8.45%. The company focuses on the research, development, and commercialization of novel therapeutics for the treatment of cancer and other diseases.
Summary
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. According to the State of Alaska Department of Revenue, the state holds $937,000 of the company’s stock. Despite some short-term volatility, analysts remain bullish on the stock due to its strong product pipeline, a growing addressable market, and strengthened financial position. As such, investors may want to consider adding Supernus Pharmaceuticals to their portfolios for potential long-term growth.
